Studies on α-glucosidase inhibitors development: Magic molecules for the treatment of carbohydrate mediated diseases

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 713-720

  Moorthy, N S H N ^a   Ramos, M J ^a   Fernandes, P A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

glucosidases; HIV; Hydrophobicity; QSAR; vdW surface area

Indexed keywords

ACARBOSE; ALORESIN A; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; AROMATIC AMINO ACID; ASPARTIC ACID; BMN 701; CASTANOSPERMINE 6 BUTYRATE; CKD 711; CKD 711A; DIPHLORETHOHYDROXYCARMALOL; GLUTAMIC ACID; HISTIDINE; LYONIRESINOL 3 O BETA DEXTRO GLUCOPYRANOSIDE; MIGLITOL; N BUTYL 1 DEOXYNOJIRIMYCIN; NATURAL PRODUCT; NEOPONKORANOL; NEOSALAPRINOL; PHENYLALANINE; QUERCETIN 3 O BETA DEXTRO XYLOPYRANOSYL (1''' 2''') BETA DEXTRO GALACTOPYRANOSIDE; TYROSINE; UNCLASSIFIED DRUG; VOGLIBOSE; ZAVASCA;

ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; CHEMICAL BOND; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; GLYCOGEN STORAGE DISEASE TYPE 2; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; LYSOSOME STORAGE DISEASE; METASTASIS; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOPHORE; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ALPHA-GLUCOSIDASES; ANIMALS; CARBOHYDRATE METABOLISM; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862625361     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712801264837     Document Type: Review

References (71)

1. Gamblin, D.P.; Scanlan, E.M.; Davis, B.G. Glycoprotein synthesis: An update. Chem. Rev., 2009, 109, 131-163.
2. Park, H.; Hwang, K.Y.; Kim, Y.H.; Oh, K.H.; Lee, J.Y.; Kim, K. Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo antidiabetic effect. Bioorg. Med. Chem. Lett., 2008, 18, 3711-3715.
3. Rawling, A.J.; Lomas, H.; Adam, W.P.; Marvin, J.R.L.; Dominic, S.A.; Shane, J.S.R.; Sarah, F.J.; George, W.J.F.; Raymond, A.D.; John, H.J.; Terry, D.B. Synthesis and biological characterization of novel N-alkyl deoxynojirimycin α-glucosidase inhibitors. ChemBioChem, 2009, 10, 1101-1105.
4. Murray, R.K.; Granner, D.K.; Mayes, P.A.; Rodwell, V.W.; Harper: Bioquimica; Atheneu: Sao Paulo, 1994, 628-646.
5. Melo, E.B.; Gomes, A.S.; Carvalho, I. α-and β-Glucosidase inhibitors: Chemical structure and biological activity. Tetrahedron, 2006, 62, 10277-10302.
6. Hwangseo, P.; Kyo, Y.H.; Kyung, H.O.; Young, H.K.; Jae, Y.L.; Keun, K. Discovery of novel α-glucosidase inhibitors based on the virtual screening with the homology-modelled protein structure. Bioorg. Med. Chem., 2008, 16, 284-292.
7. Humphries, M.J.; Matsumoto, K.; White, S.L.; Olden, K. Inhibition of experimental metastasis by Castanospermine in mice: blockage of two distinct stages of tumor colonization by oligosaccharide processing inhibitors. Cancer Res., 1986, 46, 5215-5222.
8. Rudd, P.M.; Storr, S.J.; Royle, L.; Chapman, C.J.; Hamid, U.M.; Robertson, J.F.; Murray, A.; Dwek, R.A. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiol., 2008, 18(6), 456-462.
9. Silva, C.H.T.P.; Taft, C.A. Computer aided molecular design of novel glucosidase inhibitors for AIDS treatment. J. Biomol. Struct. Dyn., 2004, 22, 59-63.
10. Shen, Q.; Shao, J.; Peng, Q.; Zhang, W.; Ma, L.; Chan, A.S.C.; Gu, L. Hydroxycoumarin derivatives: Novel and potent α-glucosidase inhibitors. J. Med. Chem., 2010, 53, 8252-8259.
11. Karpas, A.; Fleet, G.W.J.; Dwek, R.A.; Petursson, S.; Namgoong, S.K.; Ramsden, N.G.; Jacob, G.S.; Rademacher, T.W. Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc. Natl. Acad. Sci. USA, 1988, 85, 9229-9233.
12. Zitzmann, N.; Mehta, A.S.; Carrouee, S.; Butters, T.D.; Platt, F.M.; McCauley, J.; Blumberg, B.S.; Dwek, R.A.; Block, T.M. Iminosugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. USA, 1999, 96, 11878-11882.
13. Kavitha, B.; Nagakumar, B.; Ki, H.P.; Keun, W.L. Binding mode analyses and pharmacophore model development for sulphonamide chalcone derivatives, a new class of α-glucosidase inhibitors. J. Mol. Graph. Model., 2008, 26, 1202-1212.
14. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. QSAR analysis of isosteviol derivatives as α-glucosidase inhibitors with element count and other descriptors. Lett. Drug Des. Dis., 2011, 8, 14-25.
15. Hakamata, W.; Yamamoto, E.; Muroi, M.; Mochizuki, M.; Kurihara, M.; Okuda, H.; Fukuhara, K. Design and synthesis of α-glucosidase inhibitor having DNA cleaving activity. J. Appl. Glycosci., 2006, 53, 255-260.
16. Monroe, J.D.; Gough, C.M.; Chandler, L.E.; Loch, C.M.; Ferrante, J.E.; Wright, P.W. Structure, properties, and tissue localization of apoplastic α-glucosidase in Crucifers. Plant Physiol., 1999, 119, 385-397.
17. Herscovics, A. Importance of glycosidases in mammalian glycoprotein biosynthesis. Biochem. Biophy. Acta., 1999, 1473, 96-107.
18. Poumbourios, P.; Maerz, A.L.; Drummer, H.E. Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. J. Biol. Chem., 2003, 278 (43), 42149-42160.
19. Kajimoto, T.; Node, M. Inhibitors against glycosidases as medicines. Curr. Topics Med. Chem., 2009, 9, 13-33.
20. Ren, Z.; Yao, Q.; Chen, C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab. Invest., 2002, 82(3), 245-255.
21. Braakman, I.; van Anken, E. Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic, 2000, 1, 533-539.
22. Caramelo, J.J.; Parodi, A.J. Getting in and out from calnexin/calreticulin cycle. J. Biol. Chem., 2008, 283, 10221-10225.
23. Helenius, A.; Aebi, M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem., 2004, 73, 1019-1049.
24. Suzuki, K.; Nakahara, T.; Kanie, O. 3,4-Dihydroxypyrrolidine as glycosidase inhibitor. Curr. Topics Med. Chem., 2009, 9, 34-57.
25. Tanaka, K.S.E.; Winters, G.C.; Batchelor, R.J.; Einstein, F.W.B.; Bennet, A.J. A new structural motif for the design of potent glucosidase inhibitors. J. Am. Chem. Soc., 2001, 123, 998-999.
26. Brazdova, B.; Tan, N.S.; Samoshina, N.M.; Samoshin, V.V. Novel easily accessible glucosidase inhibitors: 4-hydroxy-5-alkoxy-1,2-cyclohexanedicarboxylic acids. Carbohydr. Res., 2009, 344, 311-321.
27. Hakamata, W.; Kurihara, M.; Okuda, H.; Nishio, T.; Oku, T. Design and screening strategies for α-glucosidase inhibitors based on enzymological information. Curr. Topics Med. Chem., 2009, 9, 3-12.
28. Tomich, C.H.; da Silva, P.; Ivone, C.; Taft, C.A. Homology modelling and molecular interaction field studies of α-glucosidase as a guide to structure based drug design of novel proposed anti-HIV inhibitors. J. Comp. Aided Drug Des., 2005, 19, 83-92.
29. Park, J.-H.; Ko, S.; Park, H. Towards the virtual screening of α-glucosidase inhibitors with the homology-modeled protein structure. Bull. Korean Chem. Soc., 2008, 29(5), 921-927.
30. Moorthy, N.S.H.N.; Trivedi, P. QSAR modelling of some 2-methoxy acridones: cytotoxic in multi drug resistant cells. Int. J. Cancer Res., 2006, 2, 267-276.
31. Moorthy, N.S.H.N.; Cerqueira, N.S.; Ramos, M.J.; Fernandes, P.A. QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction. Med. Chem. Res., 2012, 21(2), 133-144. DO I10.1007/s00044-010-9510-3.
32. Moorthy, N.S.H.N.; Sousa, S.F.; Ramos, M.J.; Fernandes, P.A. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J. Enz. Inhibit. Med. Chem., 2011, 26(6), 777-791. DOI: 10.3109/14756366.2011.552885.
33. Moorthy, N.S.H.N.; Sousa, S.F.; Ramos, M.J.; Fernandes, P.A. In silico based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG and other toxic effects. J. Biomol. Screen., 2011, 16(9), 1037-46. DOI: 10.1177/1087057111414899.
34. Xu, J.; Huang, S.; Luo, H.; Li, G.; Bao, J.; Cai, S.; Wang, Y. QSAR studies on andrographolide derivatives as α-glucosidase inhibitors. Int. J. Mol. Sci., 2010, 11, 880-895.
35. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Structural analysis of structurally diverse α-glucosidase inhibitors for active site feature analysis. J. Enz. Inhibit. Med. Chem., 2011, DOI: 10.3109/14756366.2011.605359.
36. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Prediction of the relationship between the structural features of andrographolide derivatives and α-glucosidase inhibitory activity: A quantitative structure activity relationship (QSAR) study. J. Enz. Inhibit. Med. Chem., 2011, 26(1), 78-87.
37. Kumar, V.; Kumar, S.; Rani, P. Pharmacophore modeling and 3DQSAR studies on flavonoids as α-glucosidase inhibitors. Der Pharma Chemica, 2010, 2(4), 324-335.
38. Kraim, K.; Khatmi, D.; Saihi, Y.; Ferkous, F.; Brahimi, M. Quantitative structure activity relationship for the computational prediction of α-glucosidase inhibitory. Chemometr. Intell. Lab. Sys., 2009, 97, 118-126.
39. Saqip, U.; Siddiqi, M.I. 3D-QSAR studies of xanthone derivatives as human alphα-glucosidase inhibitors. Int. J. Intergrative Biol., 2009, 5(1), 13-19.
40. Gupta, N.; Saha, A.K.; Sen, R. QSAR analysis of xanthone derivative in the treatment of carbohydrate mediated diseases. J. Appl. Sci. Res., 2010, 6(5), 415-420.
41. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Topological, hydrophobicity and other descriptors on α-glucosidase inhibition: A QSAR study on xanthone derivatives. J. Enz. Inhibit. Med. Chem., 2011, 26(6), 755-766. DOI: 10.3109/14756366.2010.549089.
42. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Analysis of α-glucosidase inhibitory activity of chromenone derivatives by its molecular features: A computational study. Med. Chem., 2011, 7(6), 526-533.
43. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Comparative structural analysis of α-glucosidase inhibitors against difference species: A computational study. Archiv der Pharmazie, 2012, 345, 265-274.
44. Moorthy, N.S.H.N.; Ramos, M.J.; Fernandes, P.A. Structural analysis of α-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors, Chemometr. Intell. Lab Sys., 2011, 109(2), 101-112. DOI: 10.1016/j.chemolab.2011.02.10.
45. Truscheit, E.; Frommer, W.; Junge, B.; Muller, L.; Schmidit, D.D.; Wingender, W. Chemistry and biochemistry of microbial α-glucosidase inhibitors. Agew. Chem. Int. Ed. Engl., 1981, 20, 744-761.
46. Wehmeier, U.F.; Piepersberg, W. Biotechnology and molecular biology of the α-glucosidase inhibitor acarbose. Microbiol. Biotechnol., 2004, 63, 613-625.
47. Luo, H.; Imoto, T.; Hiji, Y. Inhibitory effect of voglibose and gymnemic acid on maltose absorption in vivo. World J. Gastroenterol., 2001, 7, 270-274.
48. Inouye, S.; Tsuruoka, T.; Ito, T.; Niida, T. Structure and synthesis of nojirimycin. Tetrahedron, 1968, 23, 2125-2144.
49. Reese, E.T.; Parrish, F.W. Nojirimycin and D-glucose-1,5-lactone as inhibitors of carbohydrases. Carbohydr. Res., 1971, 18, 381-388.
50. Asano, N.; Tomioka, E.; Kizu, H.; Matsui, K. Sugars with nitrogen in the ring isolated from the leaves of Morus bombycis. Carbohydr. Res., 1994, 253, 235-245.
51. Maeda, K.; Kakabayashi, S.; Matsubara, H. Complete amino acid sequence of an a-amylase inhibitor in wheat kernel (0.19-inhibitor). Biochim. Biophys. Acta, 1985, 828, 213-221.
52. Kim, K.Y.; Nama, K.A.; Kurihara, H.; Kim, S.M. Potent α-glucosidase inhibitors purified from the red alga Grateloupia elliptica. Phytochem., 2008, 69, 2820-2825.
53. Jong-Anurakkun, N.; Bhandari, M.R.; Kawabata, J. α-glucosidase inhibitors from Devil tree (Alstonia scholaris). Food Chem., 2007, 103, 1319-1323.
54. Gunawan-Puteri, M.D.P.T.; Kawabata, J. Novel α-glucosidase inhibitors from Macaranga tanarius leaves. Food Chem., 2010, 123, 384-389.
55. Lee, S.S.; Lin, H.C.; Chen, C.K. Acylated flavonal monorhamnosides, α-glucosidase inhibitors, from Machilus philippinensis. Phytochem., 2008, 69, 2347-2353.
56. Heo, S.J.; Hwang, J.Y.; Choi, J.I.; Han, J.S.; Kim, H.J.; Jeon, Y.J. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent α-glucosidase and a-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur. J. Pharmacol., 2009, 615, 252-256.
57. Zhang, L.; Bai, B.; Liu, X.; Wang, Y.; Li, M.; Zhao, D. α-Glucosidase inhibitors from Chinese Yam (Dioscorea opposita Thunb.). Food Chem., 2011, 126, 203-206.
58. Luo, J.C., Wang, X.B.; Ma, Li.; Kong, L.Y. Gypsophin: A novel α-glucosidase inhibitory cyclic peptide from the roots of Gypsophila oldhamiana. Bioorg. Med. Chem. Lett., 2007, 17, 4460-4463.
59. Lee, S.H.; Park, M.H.; Heo, S.J.; Kang, S.M.; Ko, S.C.; Han, J.S.; Jeon, Y.J. Dieckol isolated from Ecklonia cava inhibits α-glucosidase and a-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice. Food Chem. Toxicol., 2010, 48, 2633-2637.
60. Xie, W.; Tanabe, G.; Akaki, J.; Morikawa, T.; Ninomiya, K.; Minematsu, T.; Yoshikawa, M.; Wu, X.; Muraokaa, O. Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors. Bioorg. Med. Chem., 2011, 19(6), 2015-2022. doi: 10.1016/j.bmc.2011.01.052.
61. Jong-Anurakkun, N.; Bhandari, M.R.; Hong, G.; Kawabata, J. α-Glucosidase inhibitor from Chinese aloes. Fitoterapia, 2008, 79, 456-457.
62. Wang, H.; Dub, Y.J.; Song, H.C. α-glucosidase and a-amylase inhibitory activities of guava leaves. Food Chem., 2010, 123, 6-13.
63. Durantel, D. Celgosivir, an α-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs, 2009, 10(8), 860-870.
64. http://www.drugs.com/clinical_trials/migenix-reports-preliminarycelgosivir-viral-kinetics-study-2849.html.
65. http://www.rxpgnews.com/hepatitis-cvirus/Celgosivir_Cleared_for_Phase_IIb_Combination_Study_2047_2047.shtml.
66. http://hcvdrugs.com/.HepatitisCNewDrugPipelineNewdrugsindevelopmentforthetreatmentofhepatitis.C (Updated 15 June 2011).
67. Whitby, K.; Taylor, D.; Patel, D.; Ahmed, P.; Tyms, A.S. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir. Chem. Chemother., 2004, 15(3), 141-51.
68. http://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php (Published on January 20, 2011).
69. Kwon, Y.I.; Son, H.J.; Moon, K.S.; Kim, J.K.; Kim, J.G.; Chun, H.S.; Ahn, S.K.; Hong, C.I. Novel α-glucosidase inhibitors, CKD-711 and CKD-711a produced by Streptomyces sp. CK-4416. II. Biological properties. J. Antibiot. (Tokyo), 2002, 55 (5), 462-466.
70. Chang, H.B.; Kim, S.H.; Kwon, Y.I.; Choung, D.H.; Choi, W.K.; Kang, T.W.; Lee, S.; Kim, J.G.; Chun, H.S.; Ahn, S.K.; Hong, C.I.; Han, K.H. Novel α-glucosidase inhibitors, CKD-711 and CKD-711a produced by Streptomyces sp. CK-4416. III. Physicochemical properties and structure elucidation. J. Antibiot. (Tokyo), 2002, 55(5), 467-471.
71. Kawamori, R.; Tajima, N.; Iwamoto, Y.; Kashiwagi, A.; Shimamoto, K.; Kaku, K.; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: A randomised, doubleblind trial in Japanese individuals with impaired glucose tolerance. Lancet, 2009, 373(9675), 1607-1614.